A survey from Milan included 150 pT1ab node-negative, Her-2 positive breast cancer and showed a low risk of recurrence at 5 years, but, in patients ER positive, Her-2 overexpression was associated with a worse relapse-free survival (DFS) (Curigliano et al. 2009). Here, ERBB2 is linked to breast cancer.